Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Neovasc Inc. T.NVC


Primary Symbol: NVCN

Neovasc Inc is a specialty medical device company. It develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products the Neovasc Reducer (Reducer), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara, for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel and Europe. The company earns revenue from one source, the Reducer.


NDAQ:NVCN - Post by User

Comment by pleazu69on Apr 19, 2018 4:45am
85 Views
Post# 27909161

RE:Leerink downgraded from $5 to $2 on March 28th

RE:Leerink downgraded from $5 to $2 on March 28th$2  wow that would make allot of dreams come true
even if they downgraded to $1 thats over 1500% profit from todays prices
and that target was before the warrant money hit the bank :)

rimbus wrote: https://thefly.com/landingPageNews.php?id=2706122&headline=NVCN-Neovasc-price-target-lowered-to--from--at-Leerink

Neovasc price target lowered to $2 from $5 at Leerink Leerink analyst Danielle Antalffy lowered her price target for Neovasc to $2 from $5 to reflect significant dilution. The analyst believes the solvency risk is largely mitigated following Q4 sales of $1.2M and as Tiara clinical trials continue to progress. Antalffy reiterates an Outperform rating on the shares.


<< Previous
Bullboard Posts
Next >>